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A 29-year-old student from El Salvador, who was LFT’s with negative toxoplasma and syphilis serology 
known to be HIV positive, presented to Accident and and negative cryptococcal antigen. CMV IgG was 
Emergency department having had a generalised detected, but CMV Direct Antigen Test was negative. 
seizure. Over the previous 10 days a colleague had MRI scan showed multiple ring-enhancing lesions, the 
noticed increasingly bizarre behaviour in that he had largest in the left occipital lobe. 
been unable to recognise friends and relatives, and 
had complained of headaches, flashing lights and Questions 
nausea. O n  examination he had severe oropharyngeal 
candidiasis and was disorientated in time, person and 
place. He had a right total homonymous hemianopia 
and visual inattention on the right side. There was no 
meningism. Initial tests revealed normal FBC, U&E, 
1 .  
2. 
3. 
4. 
What is the differential diagnosis 
Which test result is unexpected 
What initial treatment is indicated 
What is the prognosis 
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Answers 
1 . Cerebral Toxoplasrna gondii, primary CNS lymphoma 
and progressive multifocal leukoencephalopathy 
(PML) together account for 80%-90% of focal 
neurological lesions. Less commonly mass lesions 
can be caused by Cryptococcus neoformans, pyogenic 
or tuberculous abscesses, and more rarely Norardia 
asteroides, TYeponema pallidurn, cytomegalovirus (CMV), 
Candida albicans and Histoplasma capsulatum. 
2. The toxoplasma serology. Despite negative serology 
(serology is negative in 3-5% of cases of toxoplasmic 
encephalitis), toxoplasmosis is still the most likely 
diagnosis. 
3. Pyrimethamine (200 mg loading dose, followed by 
50-75 mg/day oral) and sulfadiazine (4-6 g 6 h oral 
or intravenous), with folinic acid (15-20 mg/day, 
oral). Clindamycin may replace sulfadiazine if in- 
tolerance occurs of the latter. 
4. If patients are going to respond they tend to in 3 
(50%) to 7 (90%) days. Early mortality is as high 
as 16%, and 40-50% will have residual neurological 
impairment. Without secondary prophylaxis re- 
activation occurs in up to 80% of patients. Median 
survival after infection has been reported in the 
range of 224 to 490 days. 
Neurological disorders cause considerable morbidity 
and mortality in patients with AIDS. At least 40% of 
HIV-infected patients develop neurological symptoms 
during the course of their illness. With suspected toxo- 
plasmosis most centres recommend a therapeutic trial 
of antimicrobials for 10-14 days, with brain biopsy 
being reserved for non-responders or those deteriorating 
on therapy. Factors reported to be associated with 
poorer outcome include fever greater than 38.4"C, 
depression of conscious level at presentation, presence 
of multiple lesions on neuroimaging studies, previous 
opportunistic infections and the use of anticonvulsants. 
Cerebrospinal fluid (CSF) analysis generally adds little 
diagnostic information in such patients. The fluid may 
be normal or have rmld pleocytosis and elevated protein 
levels. Only 30-50% of patients have demonstrable 
anti-toxoplasma antibodies in the CSF. Newer diag- 
nostic techniques include P C R  for T gondii DNA 
in the CSF (sensitivity 50-76%; specificity 100%) and 
functional imaging techniques e.g. SPECT (single- 
photon emission computed tomography) and PET 
(positron emission tomography). These studies rely on 
rapidly dividing and growing cells taking up more 
radiolabelled substrate than inflammatory lesions, and 
are therefore useful in differentiating lymphoma from 
infections such as toxoplasmosis. 
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